Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Lung cancer, small cell
Stage/Subtype:  recurrent small cell lung cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 47 for your search:
Start Over
Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0908010555, NCT01757158
SC16LD6.5 in Recurrent Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRX16-001, NCT01901653
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRAB CTC 11-001, CAR-IST-553, NCT01941316
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00461, 13-505, 9525, P30CA006516, U01CA062490, NCT02079740
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ME-344-002, NCT02100007
Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 14-043, NCT02155465
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-1195, NCT02261805
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
A Study of Patients Receiving High-Dose Rate Brachytherapy
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 to 90
Sponsor: NCI
Protocol IDs: 090100, 09-C-0100, NCT00924027
Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-08-026, NCT01051037
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 78,256, NCT01237457
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110096, 11-C-0096, NCT01306045
Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CSOM230DUS21T, NCT01417806
Cabozantinib in Advanced Solid Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-091, NCT01588821
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01130, 12-021, CDR0000737062, IRB # 12-021, 9026, N01CM00039, P30CA008748, U01CA070095, UM1CA186691, NCT01638546
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 12-1726, NCI-2013-00402, NCT01803269
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I 225612, NCI-2013-01142, P30CA016056, NCT01876446
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13-2002.cc, NCI-2013-01644, NCT01935336
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C14018, 2013-003713-18, U1111-1154-9805, NCT02038647
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALDOXORUBICIN-P2-SCLC-01, NCT02200757
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KCP-330-006, NCT02213133
Pegylated Irinotecan NKTR 102 in Treating Patients With Refractory Brain Metastasis From Non-small Cell Lung Cancer or Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: LUN0067, NCI-2014-02101, P30CA124435, NCT02312622
Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-14136, NCI-2014-02489, NCT02351505
Natural Killer Cells and Bortezomib to Treat Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NHLBI
Protocol IDs: 080186, 08-H-0186, NCT00720785
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Small Cell Lung Cancer That Has Relapsed or Not Responded to Treatment
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 and over
Sponsor: NCI, Other
Protocol IDs: 508-08, NCI-2009-01308, P30CA036727, UNMC-50808, IRB #508-08, NCT00856037
Start Over